EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer

Histology and Histopathology

Volumn 29, Issue 4, 2014, Pages 513-521

  Martin, Vittoria ^a   Zanellato, Elena ^a   Franzetti Pellanda, Alessandra ^b   Molinari, Francesca ^a   Movilia, Alessandra ^c   Paganotti, Alessia ^d   Deantonio, Letizia ^d   De Dosso, Sara ^b   Assi, Agnese ^c   Crippa, Stefano ^a   Boldorini, Renzo ^d   Mazzucchelli, Luca ^a   Saletti, Piercarlo ^b   Frattini, Milo ^a  

^a INSTITUTE OF PATHOLOGY   (Switzerland)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c Civil Hospital   (Italy)

^d University School of Medicine   (Italy)

Author keywords

EGFR; EGFR targeted therapy; KRAS; PIK3CA; Squamous cell anal cancer

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; ANUS TUMOR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PROTO ONCOGENE; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANUS NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, ERBB-1; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, SQUAMOUS CELL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84897102912     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Akagi I., Miyashita M., Makino H., Nomura T., Hagiwara N., Takahashi K., Cho K., Mishima T., Ishibashi O., Ushijima T., Takizawa T. and Tajiri T. (2009). Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma. Int. J. Oncol. 34, 767-775.
2. Alrifai D., Popat S., Ahmed M., Gonzalez D., Nicholson A.G., Parcq J.D. and Benepal T. (2013). A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations. Lung Cancer 80, 339-340.
3. Alvarez G., Perry A., Tan B.R. and Wang H.L. (2006). Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod. Pathol. 19, 942-949.
4. Bardelli A. and Siena S. (2010). Molecular mechanisms of resistance to Cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28, 1254-1261.
5. Barmettler H., Komminoth P., Schmid M. and Duerr D. (2012). Efficacy of Cetuximab in combination with FOLFIRI in a patient with KRAS wild-type metastatic anal cancer. Case Rep. Oncol. 5, 428-433.
6. Bernardes V.F., Gleber-Netto F.O., Sousa S.F., Rocha R.M. and Aguiar M.C. (2013). EGFR status in oral squamous cell carcinoma: comparing immunohistochemistry, FISH and CISH detection in a case series study. BMJ Open 3, e002077.
7. Bertotti A., Migliardi G., Galimi F., Sassi F., Torti D., Isella C, Corà D., Di Nicolantonio F., Buscarino M., Petti C., Ribero D., Russolillo N., Muratore A., Massucco P., Pisacane A., Molinaro L, Valtorta E., Sartore-Bianchi A., Risio M., Capussotti L., Gambacorta M., Siena S., Medico E., Sapino A., Marsoni S., Comoglio P.M., Bardelli A. and Trusolino L. (2011). A molecularly annotated platform of patientderived xenografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discovery 1, 508-523.
8. Cappuzzo F., Finocchiaro G., Rossi E., Jänne P.A., Carnaghi C., Calandri C., Bencardino K., Ligorio C., Ciardiello F., Pressiani T., Destro A., Roncalli M., Crino L., Franklin W.A., Santoro A. and Varella-Garcia M. (2008). EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann. Oncol. 19, 717-723.
9. Cohen Y., Goldenberg-Cohen N., Shalmon B., Shani T., Oren S., Amariglio N., Dratviman-Storobinsky O., Shnaiderman-Shapiro A., Yahalom R., Kaplan I. and Hirshberg A. (2011). Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma. Oral Oncol. 47, 946-950.
10. Cosmic: Catalogue of Somatic Mutations in Cancer, http://cancer.sanger.ac.uk/cosmic Clinical trial database, http://clinicaltrials.gov
11. Czito B.G. and Willett C.G. (2009). Current management of anal canal cancer. Curr. Oncol. Rep. 11, 186-192.
12. De Carvalho T.G., De Carvalho A.C., Maia D.C., Ogawa J.K., Carvalho A.L. and Vettore A.L. (2013). Search for mutations in signaling pathways in head and neck squamous cell carcinoma. Oncol. Rep. 30, 334-340.
13. De Dosso S., Martin V., Zanellato E., Frattini M. and Saletti P. (2010). Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. Tumori 96, 627-629.
14. De Roock W., Jonker D.J., Di Nicolantonio F, Sartore-Bianchi A., Tu D., Siena S., Lamba S., Arena S., Frattini M., Piessevaux H., Van Cutsem E., O'Callaghan C.J., Khambata-Ford S., Zalcberg J.R., Simes J., Karapetis C.S., Bardelli A. and Tejpar S. (2010). ssociation of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304, 1812-1820.
15. Deberne M., Levy A. and Mondini M. (2013). The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-poisitive cervail cancer cell lines' in-vitro and in-vivo xenografts. Anticancer Drugs 24, 599-608.
16. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S. and Bardelli A. (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705-5712.
17. Dorsey K. and Agulnik M. (2013). Promising new molecular targeted therapies in head and neck cancer. Drugs 73, 315-325.
18. Ellis C.A and Clark G. (2000). The importance of being K-Ras. Cell Signal. 12, 425-434.
19. European Cytogeneticists Association Recommendations for FISH on histological sections of solid tumors, www.e-c-a.eu/
20. Fiala O., Pesek M., Finek J., Benesova L., Bortlicek Z. and Minarik M. (2013). Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy. Anticancer Res. 33, 1705-1711.
21. Frattini M., Ferrario C., Bressan P., Balestra D., De Cecco L., Mondellini P., Bongarzone I., Collini P., Gariboldi M., Pilotti S., Pierotti M.A. and Greco A. (2004). Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23, 7436-7440.
22. Frattini M., Saletti P., Romagnani E., Martin V., Molinari F., Ghisletta M., Camponovo A., Etienne L.L, Cavalli F. and Mazzucchelli L. (2007). PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 97, 1139-1145.
23. Frisch M. (2002). On the etiology of anal squamous carcinoma. Dan. Med. Bull. 49, 194-209.
24. Gazdar A.F. (2010). Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev. 29, 37-48.
25. Gervaz P., Buchs N. and Morel P. (2008). Diagnosis and management of anal cancer. Curr. Gastroenterol. Rep. 10, 502-506.
26. Gonzaga I.M., Soares-Lima S.C., de Santos P.T., Blanco T.C., de Reis B.S., Quintella D.C., de Oliveira I.M., de Faria P.A., Kruel C.D., Andreollo N.A., de Simão T.A. and Pinto L.F. (2012). Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas. BMC Cancer 12, 569.
27. Gou H.F., Li X., Qiu M., Cheng K., Li L.H., Dong H., Chen Y., Tang Y., Gao F., Zhao F., Men H.T., Ge J., Su J.M., Xu F., Bi F., Gao J.J.and Liu J.Y. (2013). Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma. PLoS One 8, e62175.
28. Johnson L.G., Madeleine M.M. and Newcomer L.M. (2004). Anal Cancer incidence and survival: the surveillance, epidemiology and end results experience, 1973-2000. Cancer 101, 281-288.
29. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J. and Zalcberg J.R. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765.
30. Kato H., Arao T., Matsumoto K., Fujita Y., Kimura H., Hayashi H., Nishiki K., Iwama M., Shiraishi O., Yasuda A., Shinkai M., Imano M., Imamoto H., Yasuda T., Okuno K., Shiozaki H. and Nishio K. (2013). Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int. J. Oncol. 42, 1151-1158.
31. Kendall A., Lord R. and Maisey N. (2010). Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer. Recent Pat Anticancer Drug Discov. 5, 142-151.
32. Kozaki K., Imoto I., Pimkhaokham A., Hasegawa S., Tsuda H., Omura K. and Inazawa J. (2006). PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci. 97, 1351-1358.
33. Le L.H., Chetty R. and Moore M.J. (2005). Epidermal growth factor receptor expression in anal canal carcinoma. Am. J. Clin. Pathol. 124, 20-23.
34. Lee Y., Shim H.S., Park M.S., Kim J.H., Ha S.J., Kim S.H. and Cho B.C. (2012). High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Clin. Cancer Res. 18, 1760-1768.
35. Licitra L., Perrone F., Tamborini E., Bertola L., Ghirelli C., Negri T., Orsenigo M., Filipazzi P., Pastore E., Pompilio M., Bossi P., Locati L.D., Cantu' G., Scaramellini G., Pilotti S. and Tagliabue E. (2011a). Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. Ann. Oncol. 22, 1886-1893.
36. Licitra L., Mesia R., Rivera F., Remenár E., Hitt R., Erfán J., Rottey S., Kawecki A., Zabolotnyy D., Benasso M., Störkel S., Senger S., Stroh C. and Vermorken J.B. (2011b). Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann. Oncol. 22, 1078-1087.
37. Lièvre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., Côté J.F., Tomasic G., Penna C., Ducreux M., Rougier P., Penault-Llorca F. and Laurent-Puig P. (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992-3995.
38. Lin J.K., Lin A.J., Lin C.C., Lan Y.T., Yang S.H., Li A.F. and Chang S.C. (2011). The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. J. Surg. Oncol. 104, 661-666.
39. Lukan N., Ströbel P., Willer A., Kripp M., Dinter D., Mai S., Hochhaus A. and Hofheinz R.D. (2009). Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology 77, 293-299.
40. Maeng C.H., Lee J., van Hummelen P., Park S.H., Palescandolo E., Jang J., Park H.Y., Kang S.Y., MacConaill L., Kim K.M. and Shim Y.M. (2012). High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations. PLoS One 7, e41655
41. Mao C., Qiu L.X., Liao R.Y., Du F.B., Ding H., Yang W.C., Li J. and Chen Q. (2009). KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A metaanalysis of 22 studies. Lung Cancer 69, 272-278.
42. Mao C., Liao R.Y., Qiu L.X., Wang X.W., Ding H. and Chen Q. (2011). BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a metaanalysis. Mol. Biol. Rep. 38, 2219-2223.
43. Mao C., Yang Z.Y., Hu X.F., Chen Q. and Tang J.L. (2012). PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann. Oncol. 23, 1518-1525.
44. Martin F.T., Kavanagh D. and Waldron R. (2009a). Squamous cell carcinoma of the anal canal. Surgeon 7, 232-237.
45. Martin V., Mazzucchelli L. and Frattini M. (2009b). An overview of the epidermal growth factor receptor fluorescence in situ hybridization challenge in tumour pathology. J. Clin. Pathol. 62, 314-324.
46. Martin V., Botta F., Zanellato E., Molinari F., Crippa S., Mazzucchelli L. and Frattini M. (2012). Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. Histol. Histopathol. 27, 785-792.
47. Meyer J., Willett C. and Czito B. (2010). Current and emerging treatment strategies for anal cancer. Curr. Oncol. Rep. 12, 168-174.
48. Mori R., Ishiguro H., Kimura M., Mitsui A., Sasaki H., Tomoda K., Mori Y., Ogawa R., Katada T., Kawano O., Harada K., Fujii Y. and Kuwabara Y. (2008). PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. J. Surg. Res. 145, 320-326.
49. Muhammad S., Jiang Z., Liu Z., Kaur K. and Wang X. (2013). The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. J. Gastrointest. Oncol. 4, 72-81.
50. Murugan A.K., Hong N.T., Fukui Y., Munirajan A.K. and Tsuchida N. (2008). Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int. J. Oncol. 32, 101-111.
51. Nakata Y., Uzawa N., Takahashi K., Sumino J., Michikawa C., Sato H., Sonoda I., Ohyama Y., Okada N. and Amagasa T (2011). EGFR gene copy number alteration is a better prognostic indicator than protein overexpression in oral tongue squamous cell carcinomas. Eur. J. Cancer 47, 2364-2372.
52. Nichols A.C., Palma D.A., Chow W., Tan S., Rajakumar C., Rizzo G., Fung K., Kwan K., Wehrli B., Winquist E., Koropatnick J., Mymryk J.S., Yoo J. and Barrett J.W. (2013). High frequency of activating PIK3CA mutations in human Papillomavirus-positive oropharyngeal cancer. JAMA Otolaryngol. Head Neck Surg. 139, 617-622.
53. Okano S., Yoshino T., Fujii M., Onozawa Y., Kodaira T., Fujii H., Akimoto T., Ishikura S., Oguchi M., Zenda S., de Blas B., Tahara M. and Beier F. (2013). Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck. Jpn. J. Clin. Oncol. 43, 476-482.
54. Palefsky J.M. (1994). Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem. AIDS 8, 283.
55. Paliga A., Onerheim R., Gologan A., Chong G., Spatz A., Niazi T., Garant A., Macheto D., Alcindor T. and Vuong T. (2012). EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br. J. Cancer 107, 1864-1868.
56. Patel H., Polanco-Echeverry G., Segditsas S., Volikos E., McCart A., Lai C., Guenther T., Zaitoun A., Sieber O., Ilyas M., Northover J. and Silver A. (2007). Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma. Int. J. Cancer 121, 2668-2673.
57. Personeni N., Fieuws S., Piessevaux H., De Hertogh G., De Schutter J., Biesmans B., De Roock W., Capoen A., Debiec-Rychter M., Van Laethem J.L., Peeters M., Humblet Y., Van Cutsem E. and Tejpar S. (2008). Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin. Cancer Res. 14, 5869-5876.
58. Phan L.K. and Hoff P.M. (2007). Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis. Colon Rectum 50, 395-398.
59. Psyrri A., Seiwert T.Y. and Jimeno A. (2013). Molecular pathways in head and neck cancer. Am. Soc. Clin. Oncol. Educ. Book 246-255.
60. Rebucci M., Peixoto P., Dewitte A., Wattez N., De Nuncques M.A., Rezvoy N., Vautravers-Dewas C., Buisine M.P., Guerin E., Peyrat J.P., Lartigau E. and Lansiaux A. (2011). Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. Int. J. Oncol. 38, 189-200.
61. Rössle M., Weber C.S., Züllig L., Graf N., Jochum W., Stöckli S.J., Moch H. and Huber G.F. (2013). EGFR expression and copy number changes in low T-stage oral squamous cell carcinomas. Histopathology 63, 271-288.
62. Samuels Y., Diaz L.A. Jr, Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., Rago C., Huso D.L., Lengauer C., Kinzler K.W., Vogelstein B. and Velculescu V.E. (2005). Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561-573.
63. Sartore-Bianchi A., Martini M., Molinari F., Veronese S., Nichelatti M., Artale S., Di Nicolantonio F., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S. and Bardelli A. (2009). PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies. Cancer Res. 69, 1851-1857.
64. Sartore-Bianchi A., Fieuws S., Veronese S., Moroni M., Personeni N.,Frattini M., Torri V., Cappuzzo F., Vander Borght S., Martin V., Skokan M., Santoro A., Gambacorta M., Tejpar S., Varella-Garcia M. and Siena S. (2012). Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. J. Clin. Pathol. 65, 218-223.
65. Scartozzi M., Bearzi I., Mandolesi A., Pierantoni C., Loupakis F., Zaniboni A., Negri F., Quadri A., Zorzi F., Galizia E., Berardi R., Biscotti T., Labianca R., Masi G., Falcone A. and Cascinu S. (2009). Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in KRAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 9, 303.
66. Shigaki H., Baba Y., Watanabe M., Murata A., Ishimoto T., Iwatsuki M., Iwagami S., Nosho K. and Baba H. (2013). PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin. Cancer Res. 19, 2451-2459.
67. Smilek P., Neuwirthova J. and Jarkovsky J. (2012). Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas. Neoplasma 59, 508-515.
68. Stankiewicz E., Prowse D.M. and Ng M. (2011). Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas. PloS One 6, e17517.
69. Tejani M.A., Cohen R.B. and Mehra R. (2010). The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics: Targets Therapy 4, 173-185.
70. Troy J.D., Weissfeld J.L. and Youk A.O. (2013). Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma. Head Neck Pathol. 7, 344-355.
71. Van Cutsem E., Köhne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., D'Haens G., Pintér T., Lim R., Bodoky G., Roh J.K., Folprecht G., Ruff P., Stroh C., Tejpar S., Schlichting M., Nippgen J. and Rougier P. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417.
72. Van Damme N., Deron P., Van Roy N., Demetter P., Bols A., Van Dorpe J., Baert F., Van Laethem J.L., Speleman F., Pauwels P. and Peeters M. (2010). Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer 10, 189.
73. Van Krieken J.H., Jung A., Kirchner T., Carneiro F., Seruca R., Bosman F.T., Quirke P., Fléjou J.F., Plato Hansen T., de Hertogh G., Jares P., Langner C., Hoefler G., Ligtenberg M., Tiniakos D., Tejpar S., Bevilacqua G. and Ensari A. (2008). KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 453, 417-431.
74. Varella-Garcia M., Diebold J., Eberhard D.A., Geenen K., Hirschmann A., Kockx M., Nagelmeier I., Rüschoff J., Schmitt M., Arbogast S. and Cappuzzo F. (2009). EGFR fluorescence in situ hybridization assay: guidelines for application to non-small-cell lung cancer. J. Clin. Pathol. 62, 970-977.
75. Yang Y.L., Xu K.L., Zhou Y., Gao X. and Chen L.R. (2012). Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas. Chin. Med. J. 125, 450-454.
76. Yonesaka K., Zejnullahu K., Okamoto I., Satoh T., Cappuzzo F., Souglakos J., Ercan D., Rogers A., Roncalli M., Takeda M., Fujisaka Y., Philips J., Shimizu T., Maenishi O., Cho Y., Sun J., Destro A., Taira K., Takeda K., Okabe T., Swanson J., Itoh H., Takada M., Lifshits E., Okuno K., Engelman J.A., Shivdasani R.A., Nishio K., Fukuoka M., Varella-Garcia M., Nakagawa K. and Jänne P.A. (2011). Activation of ERBB2 signaling causes resistance to the EGFR-directed rherapeutic antibody Cetuximab. Sci. Transl. Med. 3, 99-186.
77. Walker F., Abramowitz L,. Benabderrahmane D., Duval X., Descatoire V., Hénin D., Lehy T. and Aparicio T. (2009). Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. Hum. Pathol. 40, 1517-1527.
78. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R. and Cancer Genome Project. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 16, 855-867.
79. Wells A. (1999). EGF receptor. Int. J. Biochem. Cell Biol. 31, 637-643.
80. Zampino M.G., Magni E., Sonzogni A. and Renne G. (2009). K-ras status in squamous cell anal carcinoma (SCC): it's time for targetoriented treatment? Cancer Chemother. Pharmacol. 65, 197-199.